Is ANRO or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -46.46% -39.09% Palisade Bio N/A -33.47% -31.79%

Does the media prefer ANRO or PALI?

In the previous week, Alto Neuroscience had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Alto Neuroscience and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Alto Neuroscience's score of 0.57 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SPTX or PALI more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Seaport Therapeutics N/A N/A N/A Palisade Bio N/A -33.47% -31.79%

Does the media favor SPTX or PALI?

In the previous week, Seaport Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Seaport Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Seaport Therapeutics' score of 0.81 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CRON or PALI?

Cronos Group has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group $146.59M 8.20 -$9.45M $0.20 16.30 Palisade Bio $250K 1,425.53 -$16.78M -$0.48 N/A

Does the media prefer CRON or PALI?

In the previous week, Cronos Group had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Cronos Group and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Cronos Group's score of 0.82 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PALI or CALT?

Palisade Bio currently has a consensus target price of $9.00, indicating a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, PALI or HELP?

Palisade Bio has higher revenue and earnings than Cybin. Palisade Bio is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,425.53 -$16.78M -$0.48 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is PALI or HELP more profitable?

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Cybin N/A -71.78% -64.81%

Does the media refer more to PALI or HELP?

In the previous week, Cybin had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Cybin and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Cybin's score of 0.93 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palisade Bio (PALI) Competitors

$2.04 +0.06 (+2.76%)

As of 09/3/2026 04:00 PM Eastern

Compare

PALI vs. ANRO, SPTX, CRON, CALT, and HELP

Should you buy Palisade Bio stock or one of its competitors? Palisade Bio's main competitors and comparable companies include Alto Neuroscience (ANRO), Seaport Therapeutics (SPTX), Cronos Group (CRON), Calliditas Therapeutics AB (publ) (CALT), and Cybin (HELP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Palisade Bio compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Alto Neuroscience presently has a consensus price target of $37.25, suggesting a potential upside of 2.99%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Alto Neuroscience had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Alto Neuroscience and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Alto Neuroscience's score of 0.57 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A

Palisade Bio's return on equity of -33.47% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Palisade Bio	N/A	-33.47%	-31.79%

Alto Neuroscience has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

11.8% of Palisade Bio shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Palisade Bio beats Alto Neuroscience on 12 of the 15 factors compared between the two stocks.

How does Palisade Bio compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Seaport Therapeutics currently has a consensus price target of $37.33, indicating a potential upside of 53.70%. Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Palisade Bio	N/A	-33.47%	-31.79%

Palisade Bio has higher revenue and earnings than Seaport Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Seaport Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Seaport Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Seaport Therapeutics' score of 0.81 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palisade Bio beats Seaport Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Cronos Group had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Cronos Group and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Cronos Group's score of 0.82 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Cronos Group has a net margin of 39.08% compared to Palisade Bio's net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Palisade Bio	N/A	-33.47%	-31.79%

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 7.8% of Cronos Group shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cronos Group currently has a consensus price target of $2.30, suggesting a potential downside of 29.45%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cronos Group has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.20	-$9.45M	$0.20	16.30
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A

Summary

Cronos Group beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Palisade Bio (NASDAQ:PALI) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Palisade Bio had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Palisade Bio and 0 mentions for Calliditas Therapeutics AB (publ). Palisade Bio's average media sentiment score of 1.31 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Palisade Bio	Positive
Calliditas Therapeutics AB (publ)	Neutral

Palisade Bio has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Palisade Bio currently has a consensus target price of $9.00, indicating a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Palisade Bio has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Palisade Bio's return on equity of -33.47% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Palisade Bio has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Palisade Bio beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Cybin?

Palisade Bio (NASDAQ:PALI) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Palisade Bio has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Cybin has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Cybin had 2 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Cybin and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.31 beat Cybin's score of 0.93 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than Cybin. Palisade Bio is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Cybin	N/A	-71.78%	-64.81%

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Palisade Bio presently has a consensus target price of $9.00, indicating a potential upside of 340.10%. Cybin has a consensus target price of $48.60, indicating a potential upside of 312.91%. Given Palisade Bio's higher probable upside, analysts clearly believe Palisade Bio is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Palisade Bio beats Cybin on 10 of the 14 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$346.80M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-4.26	787.27	273.29	25.38
Price / Sales	1,425.53	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	2.92	12.33	12.89	6.14
Net Income	-$16.78M	$2.82B	$3.47B	$349.01M
7 Day Performance	2.25%	2.59%	0.60%	-0.27%
1 Month Performance	-1.21%	6.95%	5.73%	0.68%
1 Year Performance	223.22%	9.45%	25.35%	14.84%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PALI Palisade Bio	2.7361 of 5 stars	$2.05 +2.8%	$9.00 +340.1%	+215.4%	$346.80M	$250K	N/A	10
ANRO Alto Neuroscience	1.1704 of 5 stars	$36.20 -0.1%	$37.25 +2.9%	+900.6%	$1.42B	N/A	N/A	N/A
SPTX Seaport Therapeutics	2.9923 of 5 stars	$24.83 +3.1%	$38.40 +54.7%	N/A	$1.33B	N/A	N/A	N/A
CRON Cronos Group	1.7103 of 5 stars	$3.51 +2.9%	$2.30 -34.5%	+28.9%	$1.30B	$146.59M	17.55	450
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. ANRO, SPTX, CRON, CALT, and HELP

How does Palisade Bio compare to Alto Neuroscience?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Summary

How does Palisade Bio compare to Cronos Group?

Summary

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Summary

How does Palisade Bio compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. ANRO, SPTX, CRON, CALT, and HELP

How does Palisade Bio compare to Alto Neuroscience?

Do analysts rate ANRO or PALI?

Does the media prefer ANRO or PALI?

Which has preferable earnings & valuation, ANRO or PALI?

Is ANRO or PALI more profitable?

Which has more volatility and risk, ANRO or PALI?

Do insiders & institutionals hold more shares of ANRO or PALI?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Do analysts rate SPTX or PALI?

Is SPTX or PALI more profitable?

Which has better valuation and earnings, SPTX or PALI?

Do institutionals & insiders have more ownership in SPTX or PALI?

Does the media favor SPTX or PALI?

Summary

How does Palisade Bio compare to Cronos Group?

Does the media prefer CRON or PALI?

Which has more volatility and risk, CRON or PALI?

Is CRON or PALI more profitable?

Do institutionals and insiders hold more shares of CRON or PALI?

Do analysts recommend CRON or PALI?

Which has preferable valuation & earnings, CRON or PALI?

Summary

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Do insiders and institutionals have more ownership in PALI or CALT?

Does the media refer more to PALI or CALT?

Which has more volatility and risk, PALI or CALT?

Do analysts prefer PALI or CALT?

Is PALI or CALT more profitable?

Which has stronger valuation and earnings, PALI or CALT?

Summary

How does Palisade Bio compare to Cybin?

Which has more risk & volatility, PALI or HELP?

Does the media refer more to PALI or HELP?

Which has higher valuation and earnings, PALI or HELP?

Is PALI or HELP more profitable?

Do institutionals and insiders have more ownership in PALI or HELP?

Do analysts rate PALI or HELP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools